149 related articles for article (PubMed ID: 27528762)
1. Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function.
de Vinuesa AG; Bocci M; Pietras K; Ten Dijke P
Biochem Soc Trans; 2016 Aug; 44(4):1142-9. PubMed ID: 27528762
[TBL] [Abstract][Full Text] [Related]
2. Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy.
Hawinkels LJ; Garcia de Vinuesa A; Ten Dijke P
Expert Opin Investig Drugs; 2013 Nov; 22(11):1371-83. PubMed ID: 24053899
[TBL] [Abstract][Full Text] [Related]
3. Activin receptor inhibitors--dalantercept.
Gupta S; Gill D; Pal SK; Agarwal N
Curr Oncol Rep; 2015 Apr; 17(4):14. PubMed ID: 25708802
[TBL] [Abstract][Full Text] [Related]
4. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis.
Cunha SI; Pardali E; Thorikay M; Anderberg C; Hawinkels L; Goumans MJ; Seehra J; Heldin CH; ten Dijke P; Pietras K
J Exp Med; 2010 Jan; 207(1):85-100. PubMed ID: 20065063
[TBL] [Abstract][Full Text] [Related]
5. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
Wang X; Solban N; Khanna P; Callea M; Song J; Alsop DC; Pearsall RS; Atkins MB; Mier JW; Signoretti S; Alimzhanov M; Kumar R; Bhasin MK; Bhatt RS
Oncotarget; 2016 Jul; 7(27):41857-41869. PubMed ID: 27248821
[TBL] [Abstract][Full Text] [Related]
7. Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.
Hawinkels LJ; de Vinuesa AG; Paauwe M; Kruithof-de Julio M; Wiercinska E; Pardali E; Mezzanotte L; Keereweer S; Braumuller TM; Heijkants RC; Jonkers J; Löwik CW; Goumans MJ; ten Hagen TL; ten Dijke P
Clin Cancer Res; 2016 Jan; 22(1):96-106. PubMed ID: 26373572
[TBL] [Abstract][Full Text] [Related]
8. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth.
Mitchell D; Pobre EG; Mulivor AW; Grinberg AV; Castonguay R; Monnell TE; Solban N; Ucran JA; Pearsall RS; Underwood KW; Seehra J; Kumar R
Mol Cancer Ther; 2010 Feb; 9(2):379-88. PubMed ID: 20124460
[TBL] [Abstract][Full Text] [Related]
9. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis.
Scharpfenecker M; van Dinther M; Liu Z; van Bezooijen RL; Zhao Q; Pukac L; Löwik CW; ten Dijke P
J Cell Sci; 2007 Mar; 120(Pt 6):964-72. PubMed ID: 17311849
[TBL] [Abstract][Full Text] [Related]
10. ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation.
Alsina-Sanchís E; García-Ibáñez Y; Figueiredo AM; Riera-Domingo C; Figueras A; Matias-Guiu X; Casanovas O; Botella LM; Pujana MA; Riera-Mestre A; Graupera M; Viñals F
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1216-1229. PubMed ID: 29449337
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Jimeno A; Posner MR; Wirth LJ; Saba NF; Cohen RB; Popa EC; Argiris A; Grossmann KF; Sukari A; Wilson D; Zhang X; Sun J; Glasser C; Attie KM; Sherman ML; Pandya SS; Weiss J
Cancer; 2016 Dec; 122(23):3641-3649. PubMed ID: 27648727
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of vascular endothelial growth factor and bone morphogenetic protein-9/10 impairs tumor growth through inhibition of angiogenesis.
Akatsu Y; Yoshimatsu Y; Tomizawa T; Takahashi K; Katsura A; Miyazono K; Watabe T
Cancer Sci; 2017 Jan; 108(1):151-155. PubMed ID: 28133920
[TBL] [Abstract][Full Text] [Related]
13. Activin Receptor-like kinase 1: a novel anti-angiogenesis target from TGF-β family.
Vecchia L; Olivieri C; Scotti C
Mini Rev Med Chem; 2013 Aug; 13(10):1398-406. PubMed ID: 23815578
[TBL] [Abstract][Full Text] [Related]
14. ALK1 as an emerging target for antiangiogenic therapy of cancer.
Cunha SI; Pietras K
Blood; 2011 Jun; 117(26):6999-7006. PubMed ID: 21467543
[TBL] [Abstract][Full Text] [Related]
15. BMP9 (Bone Morphogenetic Protein-9)/Alk1 (Activin-Like Kinase Receptor Type I) Signaling Prevents Hyperglycemia-Induced Vascular Permeability.
Akla N; Viallard C; Popovic N; Lora Gil C; Sapieha P; Larrivée B
Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1821-1836. PubMed ID: 29880487
[TBL] [Abstract][Full Text] [Related]
16. Caveolin-1 interacts and cooperates with the transforming growth factor-beta type I receptor ALK1 in endothelial caveolae.
Santibanez JF; Blanco FJ; Garrido-Martin EM; Sanz-Rodriguez F; del Pozo MA; Bernabeu C
Cardiovasc Res; 2008 Mar; 77(4):791-9. PubMed ID: 18065769
[TBL] [Abstract][Full Text] [Related]
17. Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex.
Townson SA; Martinez-Hackert E; Greppi C; Lowden P; Sako D; Liu J; Ucran JA; Liharska K; Underwood KW; Seehra J; Kumar R; Grinberg AV
J Biol Chem; 2012 Aug; 287(33):27313-25. PubMed ID: 22718755
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?
Bhatt RS; Atkins MB
Clin Cancer Res; 2014 Jun; 20(11):2838-45. PubMed ID: 24714770
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.
Bendell JC; Gordon MS; Hurwitz HI; Jones SF; Mendelson DS; Blobe GC; Agarwal N; Condon CH; Wilson D; Pearsall AE; Yang Y; McClure T; Attie KM; Sherman ML; Sharma S
Clin Cancer Res; 2014 Jan; 20(2):480-9. PubMed ID: 24173543
[TBL] [Abstract][Full Text] [Related]
20. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting.
van Meeteren LA; Thorikay M; Bergqvist S; Pardali E; Stampino CG; Hu-Lowe D; Goumans MJ; ten Dijke P
J Biol Chem; 2012 May; 287(22):18551-61. PubMed ID: 22493445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
